Company History Ireland
1994
Combivent was introduced for the treatment of Chronic Obstructive Pulmonary Disease.
1996
Mobic was introduced for the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.
1998
Assasantin Retard introduced for the prevention of secondary stroke and TIA. Viramune an antiviral treatment for
HIV-1 Infection also introduced.
1999
Micardis was introduced for the treatment of hypertension. Cardiology and Respiratory Divisions established.
2001
Metalyse was introduced a treatment for dissolving blood clots associated with heart attacks.
2002
Spiriva was introduced with Pfizer for the treatment of Chronic Obstructive Pulmonary Disease.
2004
Mirapexin became available from Boehringer Ingelheim for the treatment of Parkinson’s Disease and Restless Leg Syndrome.
2008
Pradaxa was introduced for the prevention of Venous Thromboembolism after knee and hip replacement surgery.